CA3014575A1 - Methods of treating lactose intolerance - Google Patents

Methods of treating lactose intolerance Download PDF

Info

Publication number
CA3014575A1
CA3014575A1 CA3014575A CA3014575A CA3014575A1 CA 3014575 A1 CA3014575 A1 CA 3014575A1 CA 3014575 A CA3014575 A CA 3014575A CA 3014575 A CA3014575 A CA 3014575A CA 3014575 A1 CA3014575 A1 CA 3014575A1
Authority
CA
Canada
Prior art keywords
linoleic acid
acid
conjugated linoleic
patient
lct
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3014575A
Other languages
English (en)
French (fr)
Inventor
Marie MCNULTY
Francesca Viti
Salvatore Bellinvia
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nogra Pharma Ltd
Original Assignee
Nogra Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nogra Pharma Ltd filed Critical Nogra Pharma Ltd
Publication of CA3014575A1 publication Critical patent/CA3014575A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
CA3014575A 2016-02-26 2017-02-27 Methods of treating lactose intolerance Pending CA3014575A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662300376P 2016-02-26 2016-02-26
US62/300,376 2016-02-26
PCT/EP2017/054526 WO2017144725A1 (en) 2016-02-26 2017-02-27 Methods of treating lactose intolerance

Publications (1)

Publication Number Publication Date
CA3014575A1 true CA3014575A1 (en) 2017-08-31

Family

ID=58162625

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3014575A Pending CA3014575A1 (en) 2016-02-26 2017-02-27 Methods of treating lactose intolerance

Country Status (6)

Country Link
US (1) US20190046490A1 (enExample)
EP (1) EP3419616A1 (enExample)
JP (1) JP7125350B2 (enExample)
CA (1) CA3014575A1 (enExample)
MA (1) MA43682A (enExample)
WO (1) WO2017144725A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2805746B1 (en) 2009-02-16 2020-05-06 Nogra Pharma Limited Alkylamido compounds and uses thereof
JP6301844B2 (ja) 2012-02-09 2018-03-28 ノグラ ファーマ リミテッド 線維症の処置方法
SI3921299T1 (sl) 2019-02-08 2025-03-31 Nogra Pharma Limited Postopek izdelave 3-(4'-aminofenil)-2-metoksipropionske kisline in njenih analogov in vmesnih proizvodov

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8302708D0 (en) * 1983-02-01 1983-03-02 Efamol Ltd Pharmaceutical and dietary composition
CA2313626A1 (en) * 1997-12-12 1999-06-17 Purdue Research Foundation Methods and compositions for treating diabetes
US7015249B1 (en) * 1997-12-12 2006-03-21 Purdue Research Foundation Methods and compositions for treating diabetes
WO2003043569A2 (en) * 2001-11-16 2003-05-30 Nutrition 21, Inc. Trans-10, cis-12 conjugated linoleic acid isomer for the treatment of diseases
EP1719543A1 (en) * 2005-05-04 2006-11-08 Asan Labs., Ltd. Use of histone deacetylase inhibitors for the treatment of gastrointestinal distress
WO2007096148A1 (en) * 2006-02-23 2007-08-30 Lipid Nutrition B.V. Immunoregulation
IE20070129A1 (en) * 2007-02-28 2008-12-24 Giuliani Int Ltd Ppar-gamma agonists stimulate enteric defensin expression
US20090264520A1 (en) * 2008-04-21 2009-10-22 Asha Lipid Sciences, Inc. Lipid-containing compositions and methods of use thereof
RS56049B1 (sr) 2008-11-13 2017-09-29 Nogra Pharma Ltd Antisens kompozicije i postupci za pripremu i upotrebu istih
AU2013248397A1 (en) * 2012-04-18 2014-10-02 Nogra Pharma Limited Methods of treating lactose intolerance
JP6096179B2 (ja) * 2012-05-10 2017-03-15 国立大学法人岩手大学 ラクターゼ活性を有するタンパク質、該タンパク質をコードする遺伝子、該遺伝子を含有する組み換えベクター、形質転換体、及びその製造方法並びに用途
WO2014154683A1 (en) * 2013-03-26 2014-10-02 Lipid Therapeutics Gmbh Pharmaceutical formulation comprising phosphatidylcholine for the treatment of ulcerative colitis

Also Published As

Publication number Publication date
WO2017144725A1 (en) 2017-08-31
JP7125350B2 (ja) 2022-08-24
EP3419616A1 (en) 2019-01-02
US20190046490A1 (en) 2019-02-14
JP2019510745A (ja) 2019-04-18
MA43682A (fr) 2018-11-28

Similar Documents

Publication Publication Date Title
Jia et al. Histone deacetylase (HDAC) inhibitors targeting HDAC3 and HDAC1 ameliorate polyglutamine-elicited phenotypes in model systems of Huntington's disease
Wu et al. Oxidative stress modulates complement factor H expression in retinal pigmented epithelial cells by acetylation of FOXO3
AU2019217041B2 (en) Compositions and methods for the induction of CD8+ T-cells
Stojancevic et al. The impact of farnesoid X receptor activation on intestinal permeability in inflammatory bowel disease
Moleón et al. Protective effect of microbiota-derived short chain fatty acids on vascular dysfunction in mice with systemic lupus erythematosus induced by toll like receptor 7 activation
US9682050B2 (en) Methods of treating lactose intolerance
Zhang et al. Protein nutritional support: the classical and potential new mechanisms in the prevention and therapy of sarcopenia
CN107428652A (zh) 用于治疗炎性疾病、退行性疾病和神经退行性疾病的化合物、组合物和方法
JP7570100B2 (ja) 老化細胞を除去する方法、および老化細胞の調製方法
Dolowschiak et al. Potentiation of epithelial innate host responses by intercellular communication
Jin et al. Regulation of oxidative stress in the intestine of piglets after enterotoxigenic Escherichia coli (ETEC) infection
US20160129012A1 (en) Compositions and methods for treating allergic inflammation through inhibition of ntrk1
JP7125350B2 (ja) ラクトース不耐性を処置する方法
JP2016539098A (ja) 網膜の血管障害を治療又は予防する方法
JP2008501316A (ja) ラクトバシルスｇｇ由来プロバイオティック化合物及びそれらの使用
Yu et al. Maintenance of glutamine synthetase expression alleviates endotoxin‐induced sepsis via alpha‐ketoglutarate‐mediated demethylation
Okada et al. Intermittent fasting prompted recovery from dextran sulfate sodium-induced colitis in mice
Wu et al. Epigallocatechin-3-gallate sensitizes IFN-γ-stimulated CD4+ T cells to apoptosis via alternative activation of STAT1
Ishii et al. Gastrectomy increases the expression of hepatic cytochrome P450 3A by increasing lithocholic acid-producing enteric bacteria in mice
JP2021526526A (ja) 細菌株を含む組成物
EP1993530A2 (en) Use of dha and ara in the preparation of a composition for regulating gene expression
WO2022186170A1 (ja) 脳血管障害を予防または治療するための組成物
Lin et al. MiR-155 protects against sepsis-induced cardiomyocyte apoptosis via activation of NO/cGMP signaling pathway by eNOS
US20120122787A1 (en) Methods for treating polycystic kidney disease (pkd) or other cyst forming diseases
CN116159048A (zh) 岩藻黄素在制备治疗nlrp3诱导的肝细胞焦亡相关疾病的药物中的应用

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220202

EEER Examination request

Effective date: 20220202

EEER Examination request

Effective date: 20220202

EEER Examination request

Effective date: 20220202